康芝药业
(300086)
| 流通市值：20.93亿 | | | 总市值：21.62亿 |
| 流通股本：4.41亿 | | | 总股本：4.55亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 195,849,316.05 | 144,887,847.09 | 96,573,833.91 | 466,122,703.87 |
| 营业收入 | 195,849,316.05 | 144,887,847.09 | 96,573,833.91 | 466,122,703.87 |
| 二、营业总成本 | 280,153,239.97 | 184,674,015.53 | 105,357,588.5 | 650,931,951.28 |
| 营业成本 | 93,968,542.11 | 65,591,041.67 | 38,085,327.99 | 213,477,662.16 |
| 税金及附加 | 9,850,238.9 | 6,791,893.28 | 3,754,922.08 | 14,196,986.73 |
| 销售费用 | 73,917,361.01 | 53,087,822.16 | 32,442,507.76 | 265,040,987.26 |
| 管理费用 | 79,775,582.58 | 45,562,716 | 23,980,751.69 | 121,232,452.63 |
| 研发费用 | 9,460,701.33 | 6,404,540.16 | 3,546,412.09 | 19,102,615.4 |
| 财务费用 | 13,180,814.04 | 7,236,002.26 | 3,547,666.89 | 17,881,247.1 |
| 其中:利息费用 | 12,962,685.54 | 7,187,674.81 | 3,531,840 | 17,865,052.16 |
| 其中:利息收入 | 30,637.44 | 26,382.21 | 20,836.79 | 222,601.67 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | -37,040,780.83 |
| 加:投资收益 | - | - | - | 1,448,606.93 |
| 资产处置收益 | -1,281.41 | -1,281.41 | -1,281.41 | 473,746.05 |
| 资产减值损失(新) | 1,309,420.03 | 1,676,348.16 | 1,683,328.32 | -56,137,235.23 |
| 信用减值损失(新) | -2,303,548.75 | -1,430,727.21 | -356,805.17 | 11,873,348.84 |
| 其他收益 | 12,719,417.53 | 11,887,495.95 | 996,020.7 | 6,883,622.32 |
| 四、营业利润 | -72,579,916.52 | -27,654,332.95 | -6,462,492.15 | -257,307,939.33 |
| 加:营业外收入 | 280,858.44 | 97,081.79 | 145,132.15 | 693,931.27 |
| 减:营业外支出 | 91,934.4 | 91,773.99 | 70,614.8 | 2,858,141.59 |
| 五、利润总额 | -72,390,992.48 | -27,649,025.15 | -6,387,974.8 | -259,472,149.65 |
| 减:所得税费用 | 4,546,187.3 | 5,884,957.36 | 5,751,061.75 | -25,443,282.17 |
| 六、净利润 | -76,937,179.78 | -33,533,982.51 | -12,139,036.55 | -234,028,867.48 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -76,937,179.78 | -33,533,982.51 | -12,139,036.55 | -234,028,867.48 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -75,791,195.73 | -32,766,488.74 | -11,749,745.07 | -230,138,658.52 |
| 少数股东损益 | -1,145,984.05 | -767,493.77 | -389,291.48 | -3,890,208.96 |
| 扣除非经常损益后的净利润 | -84,674,433.24 | -41,430,709.29 | -11,895,517.57 | -203,008,509.18 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.17 | -0.07 | -0.03 | -0.51 |
| (二)稀释每股收益 | -0.17 | -0.07 | -0.03 | -0.51 |
| 八、其他综合收益 | - | - | - | 14,335,824.51 |
| 归属于母公司股东的其他综合收益 | - | - | - | 14,335,824.51 |
| 九、综合收益总额 | -76,937,179.78 | -33,533,982.51 | -12,139,036.55 | -219,693,042.97 |
| 归属于母公司股东的综合收益总额 | -75,791,195.73 | -32,766,488.74 | -11,749,745.07 | -215,802,834.01 |
| 归属于少数股东的综合收益总额 | -1,145,984.05 | -767,493.77 | -389,291.48 | -3,890,208.96 |
| 公告日期 | 2026-10-26 | 2026-08-27 | 2026-04-29 | 2026-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |